研究人员针对 ARID1A 缺陷型卵巢透明细胞癌（OCCC）治疗难题，研究靶向 USP8，发现其可诱导合成致死，有望用于精准治疗。

The Institute of Cancer Research, London, is seeking a partner to continue the development of ARID1A and other BAF-complex genes as cancer biomarkers for predicting sensitivity to ATRi. More about ...

These cells were used to study how genetic alterations in ARID1A impact the genetic programs of EMT and the function of the ZIC2 gene. The analyses employed advanced techniques such as RNA-seq and ...

This study has revealed how the ZIC2 gene, in collaboration with the ARID1A-BAF complex, plays a crucial role in a process known as epithelial-to-mesenchymal transition (EMT). This process enables ...

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S.